XML 58 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock (Series A-F)
Convertible Preferred Stock Series AA
Convertible Preferred Stock Series BB
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2019 $ (68,662)         $ 23,650 $ (92,312)  
Temporary equity, Beginning balance, shares at Dec. 31, 2019   15,257,663            
Temporary equity, Beginning balance at Dec. 31, 2019   $ 47,545            
Beginning balance, shares at Dec. 31, 2019         369,491      
Stock-based compensation expense 1,492         1,492    
Conversion of preferred stock into common stock 47,545         47,545    
Temporary equity, Conversion of preferred stock into common stock, shares   (15,257,663)            
Temporary equity, Conversion of preferred stock into common stock   $ (47,545)            
Conversion of preferred stock into common stock, shares         627,871      
Conversion of common stock into series AA preferred stock (17,274)         (17,274)    
Temporary equity, Conversion of common stock into series AA preferred stock, shares     210,310,025          
Temporary equity, Conversion of common stock into series AA preferred stock     $ 17,274          
Conversion of common stock into series AA preferred stock, shares         (148,732)      
Preferred stock issued in exchange for note redemption     $ 18,050          
Preferred stock issued in exchange for note redemption, shares     219,764,872          
Issuance of preferred stock     $ 26,087 $ 10,925        
Issuance of preferred stock, shares     317,608,275 52,680,306        
Issuance of common stock, net of issuance costs, shares         705,750      
Exercise of options into common stock $ 15         15    
Exercise of options into common stock, Shares 16,666       16,666      
Issuance of common stock related to Alvaxa IPR&D acquisition $ 541         541    
Issuance of common stock related to Alvaxa IPR&D acquisition, Shares         304,376      
Net loss (20,100)           (20,100)  
Ending balance at Dec. 31, 2020 (56,443)         55,969 (112,412)  
Temporary equity, Ending balance, shares at Dec. 31, 2020     747,683,172 52,680,306        
Temporary equity, Ending balance at Dec. 31, 2020     $ 61,411 $ 10,925        
Ending balance, shares at Dec. 31, 2020         1,875,422      
Stock-based compensation expense 5,657         5,657    
Conversion of preferred stock into common stock 95,828       $ 2 95,826    
Temporary equity, Conversion of preferred stock into common stock, shares     (747,683,172) (165,956,208)        
Temporary equity, Conversion of preferred stock into common stock     $ (61,411) $ (34,416)        
Conversion of preferred stock into common stock, shares         19,034,069      
Issuance of preferred stock       $ 23,491        
Issuance of preferred stock, shares       113,275,902        
Issuance of common stock, net of issuance costs 138,489       $ 1 138,488    
Issuance of common stock, net of issuance costs, shares         8,030,295      
Exercise of options into common stock $ 28         28    
Exercise of options into common stock, Shares 8,834       8,834      
Issuance of common stock under the employee stock purchase plan $ 80         80    
Issuance of common stock under the employee stock purchase plan, Shares         11,700      
Exercise of common stock warrants 1         1    
Exercise of common stock warrants, Shares         1,648,709      
Unrealized loss on marketable securities (333)             $ (333)
Net loss (36,794)           (36,794)  
Ending balance at Dec. 31, 2021 $ 146,513       $ 3 $ 296,049 $ (149,206) $ (333)
Ending balance, shares at Dec. 31, 2021         30,609,029